Peter Kerpedjiev needed a crash course in genetics. A software engineer with some training in bioinformatics, he was pursuing a PhD and thought it would really help to know some fundamentals of biology. “If I wanted to have an intelligent conversation with someone, what genes do I need to know about?” he wondered.
Kerpedjiev went straight to the data. For years, the US National Library of Medicine (NLM) has been systematically tagging almost every paper in its popular PubMed database that contains some information about what a gene does. Kerpedjiev extracted all the papers marked as describing the structure, function or location of a gene or the protein it encodes.
Sorting through the records, he compiled a list of the most studied genes of all time — a sort of ‘top hits’ of the human genome, and several other genomes besides.
Heading the list, he found, is a gene called TP53. Three years ago, when Kerpedjiev first did his analysis, researchers had scrutinized the gene or the protein it produces, p53, in some 6,600 papers. Today, that number is at about 8,500 and counting. On average, around two papers are published each day describing new details of the basic biology of TP53.
Its popularity shouldn’t come as news to most biologists. The gene is a tumour suppressor, and widely known as the ‘guardian of the genome’. It is mutated in roughly half of all human cancers. “That explains its staying power,” says Bert Vogelstein, a cancer geneticist at the Johns Hopkins University School of Medicine in Baltimore, Maryland. In cancer, he says, “there’s no gene more important”.
But some chart-topping genes are less well known — including some that rose to prominence in bygone eras of genetic research, only to fall out of fashion as technology progressed. “The list was surprising,” says Kerpedjiev, now a postdoc studying genomic-data visualization at Harvard Medical School in Boston, Massachusetts. “Some genes were predictable; others were completely unexpected.”
To find out more, Nature worked with Kerpedjiev to analyse the most studied genes of all time (see ‘The top 10’). The exercise offers more than a conversation starter: it sheds light on important trends in biomedical research, revealing how concerns over specific diseases or public-health issues have shifted research priorities towards underlying genes. It also shows how just a few genes, many of which span disciplines and disease areas, have dominated research.
Out of the 20,000 or so protein-coding genes in the human genome, just 100 account for more than one-quarter of the papers tagged by the NLM. Thousands go unstudied in any given year. “It’s revealing how much we don’t know about because we just don’t bother to research it,” says Helen Anne Curry, a science historian at the University of Cambridge, UK.
In and out of fashion
In 2002, just after the first drafts of the human genome were published, the NLM started systematically adding ‘gene reference into function’, or GeneRIF, tags to papers1. It has extended that annotation back to the 1960s, sometimes using other databases to help fill in the details. It is not a perfectly curated record. “In general, the data set is somewhat noisy,” says Terence Murphy, a staff scientist at the NLM in Bethesda, Maryland. There’s probably some sampling bias for papers published before 2002, he warns. That means that some genes are over-represented and a few may be erroneously missing. “But it’s not awful,” Murphy says. “As you aggregate over multiple genes, that potentially reduces some of these biases.”
With that caveat noted, the PubMed records reveal a few distinct historical periods in which gene-related papers tended to focus on particular hot topics (see ‘Fashionable genes through the years’). Before the mid-1980s, for example, much genetic research centred on haemoglobin, the oxygen-carrying molecule found in red blood cells. More than 10% of all studies on human genetics before 1985 were about haemoglobin in some way.
At the time, researchers were still building on the early work of Linus Pauling and Vernon Ingram, trailblazing biochemists who pioneered the study of disease at a molecular level with discoveries in the 1940s and 1950s of how abnormal haemoglobin caused sickle-cell disease. Molecular biologist Max Perutz, who won a share in the 1962 Nobel Prize in Chemistry for his 3D map of haemoglobin’s structure, continued to explore how the protein’s shape related to its function for decades afterwards.
According to Alan Schechter, a physician-scientist and senior historical consultant at the US National Institutes of Health in Bethesda, the haemoglobin genes — more than any others at the time — offered “an entryway to understanding and perhaps treating a molecular disease”.
A sickle-cell researcher himself, Schechter says that such genes were a focus of conversation both at major genetics meetings and at blood-disease meetings in the 1970s and early 1980s. But as researchers gained access to new technologies for sequencing and manipulating DNA, they started to move on to other genes and diseases, including a then-mysterious infection that was predominantly striking down gay men.
Even before the 1983 discovery that HIV was the cause of AIDS, clinical immunologists such as David Klatzmann had noticed a peculiar pattern among people with the illness. “I was just struck by the fact that these people had no T4 cells,” recalls Klatzmann, who is now at Pierre and Marie Curie University in Paris. He showed2 in cell-culture experiments that HIV seemed to selectively infect and destroy these cells, a subset of the immune system’s T cells. The question was: how was the virus getting into the cell?
Klatzmann reasoned that the surface protein (later called CD4) that immunologists used to define this set of cells might also serve as the receptor through which HIV entered the cell. He was right, as he reported3 in a study published in December 1984, alongside a similar paper4 from molecular virologist Robin Weiss, then at the Institute of Cancer Research in London, and his colleagues.
Within three years, CD4 was the top gene in the biomedical literature. It remained so from 1987 to 1996, a period in which it accounted for 1–2% of all the tags tallied by the NLM.
That attention stemmed in part from efforts to tackle the emerging AIDS crisis. In the late 1980s, for example, several companies dabbled with the idea of engineering therapeutic forms of the CD4 protein that could mop up HIV particles before they infected healthy cells. But results from small human trials proved “underwhelming”, says Jeffrey Lifson, director of the AIDS and Cancer Virus Program at the US National Cancer Institute in Frederick, Maryland.
An even bigger part of CD4’s popularity had to do with basic immunology. In 1986, researchers realized that CD4-expressing T cells could be subdivided into two distinct populations — one that eliminates cell-infecting bacteria and viruses, and one that guards against parasites such as worms, which cause illness without invading cells. “It was a fairly exciting time, because we really understood very little,” says Dan Littman, an immunologist at the New York University School of Medicine. Just the year before, he had helped to clone the DNA that encodes CD4 and insert it into bacteria5, so that vast quantities of the protein could be made for research.
A decade later, Littman also co-led one of three teams to show6 that to enter cells, HIV uses another receptor alongside CD4: a protein identified as CCR5. These, and a second co-receptor called CXCR4, have remained the focus of intensive, global HIV research ever since, with the goal — as-yet unfulfilled — of blocking the virus’s entry into cells.
Fifteen minutes of fame
By the early 1990s, TP53 was already ascendant. But before it climbed to the top of the human gene ladder, there were a few years in which a lesser-known gene called GRB2 was in the spotlight.
At the time, researchers were starting to identify the specific protein interactions involved in cell communication. Thanks to pioneering work by cell biologist Tony Pawson, scientists knew that some small intracellular proteins contained a module called SH2, which could bind to activated proteins at the surface of cells and relay a signal to the nucleus.
In 1992, Joseph Schlessinger, a biochemist at the Yale University School of Medicine in New Haven, Connecticut, showed7 that the protein encoded by GRB2 — growth factor receptor-bound protein 2 — was that relay point. It contains an SH2 module as well as two domains that activate proteins involved in cell growth and survival. “It’s a molecular matchmaker,” Schlessinger says.
Other researchers soon filled in the gaps, opening a field of study in signal transduction. And although many other building blocks of cell signalling were soon unearthed — ultimately leading to treatments for cancer, autoimmune disorders, diabetes and heart disease — GRB2 stayed at the forefront and was the top-referenced gene for three years in the late 1990s.
In part, that was because GRB2 “was the first physical connection between two parts of the signal-transduction cascade”, says Peter van der Geer, a biochemist at San Diego State University in California. Furthermore, “it’s involved in so many different aspects of cellular regulation”.
GRB2 is something of an outlier in the most-studied list. It’s not a direct cause of disease; nor is it a drug target, which perhaps explains why its moment in the sun was fleeting. “You have some rising stars that fall down very quickly because they have no clinical value,” says Thierry Soussi, a long-time TP53 researcher at the Karolinska Institute in Stockholm and Pierre and Marie Curie University. Genes with staying power usually show some sort of therapeutic potential that attracts funding agencies’ support. “It’s always like that,” Soussi says. “The importance of a gene is linked to its clinical value.”
It can also be linked to certain properties of the gene, such as the levels at which it is expressed, how much it varies between populations and the characteristics of its structure. That’s according to an analysis by Thomas Stoeger, a systems biologist at Northwestern University in Evanston, Illinois, who reported this month at a symposium in Heidelberg, Germany, that he could predict which genes would garner the most attention, simply by plugging such attributes into an algorithm.
Stoeger thinks that the reasons for these associations largely boil down to what he calls discoverability. The popular genes happened to be in hot areas of biology and could be probed with the tools available at the time. “It’s easier to study some things than others,” says Stoeger — and that’s a problem, because vast numbers of genes remain uncharacterized and underexplored, leaving major gaps in the understanding of human health and disease.
Curry also points to “intertwined technical, social and economic factors” shaped by politicians, drugmakers and patient advocates.
Right place, right time
Stoeger has also tracked how the general features of popular genes have changed over time. He found, for example, that in the 1980s, researchers focused largely on genes whose protein products were found outside cells. That’s probably because these proteins were easiest to isolate and study. Only more recently did attention shift towards genes whose products are found inside the cell.
That shift happened alongside the publication of the human genome, says Stoeger. The advance would have opened up a larger percentage of genes to enquiry.
Many of the most explored genes, however, don’t fit these larger trends. The p53 protein, for example, is active inside the nucleus. Yet TP53 became the most studied gene around 2000. It, like many of the genes that came to dominate biological research, was not properly understood after its initial discovery — which may explain why it took several decades after the 1979 characterization of the protein for the gene to rise to the top spot in the literature.
At first, the cancer-research community mistook it for an oncogene — one that, when mutated, drives the development of cancer. It wasn’t until 1989 that Suzanne Baker, a graduate student in Vogelstein’s lab, showed8 that it was actually a tumour suppressor. Only then did functional studies of the gene really begin to pick up steam. “You can see from the spike in publications that go up essentially at that point that there were a lot of people who were really very interested,” says Baker, now a brain-tumour researcher at the St. Jude Children’s Research Hospital in Memphis, Tennessee.
Research into human cancer also brought scientists to TNF, the runner-up to TP53 as the most-referenced human gene of all time, with more than 5,300 citations in the NLM data (see ‘Top genes’). It encodes a protein — tumour necrosis factor — named in 1975 because of its ability to kill cancer cells. But anticancer action proved not to be TNF’s main function. Therapeutic forms of the TNF protein were highly toxic when tested in people.
The gene turned out to be a mediator of inflammation; its effect on tumours was secondary. Once that became clear in the mid-1980s, attention quickly shifted to testing antibodies that block its action. Now, anti-TNF therapies are mainstays of treatment for inflammatory disorders such as rheumatoid arthritis, collectively pulling in tens of billions of dollars in annual sales worldwide.
“This is an example where the knowledge of the gene and the gene product has relatively quickly changed the health of the world,” says Kevin Tracey, a neurosurgeon and immunologist at the Feinstein Institute for Medical Research in Manhasset, New York.
TP53’s dominance was briefly interrupted by another gene, APOE. First described in the mid-1970s as a transporter involved in clearing cholesterol from the blood, the APOE protein was “seriously considered” as a lipid-lowering treatment for preventing heart disease, says Robert Mahley, a pioneer in the field at the University of California, San Francisco, who tested the approach in rabbits9.
Ultimately, the creation of statins in the late 1980s doomed this strategy to the dustbin of pharmaceutical history. But then, neuroscientist Allen Roses and his colleagues found the APOE protein bound up in the sticky brain plaques of people with Alzheimer’s disease. They showed10 in 1993 that one particular form of the gene, APOE4, was associated with a greatly increased risk of the disease.
This generated much wider interest in the gene. Still, it took time to move up the most-studied chart. “The reception was very cool,” recalls Ann Saunders, a neurogeneticist and chief executive of Zinfandel Pharmaceuticals in Chapel Hill, North Carolina, who collaborated with Roses, her late husband. The amyloid hypothesis, which states that build-up of a protein fragment called amyloid-β is responsible for the disease, was all the rage in the Alzheimer’s-research community at the time. And few researchers seemed interested in finding out what a cholesterol-transport protein had to do with the disease. But the genetic link between APOE4 and Alzheimer’s risk proved “irrefutable”, Mahley says, and in 2001, APOE briefly overtook TP53. It remains in the all-time top five, at least for humans (see ‘Beyond human’).
Like other popular genes, APOE is well studied because it’s central to one of the biggest unsolved health problems of the day. But it’s also important because anti-amyloid therapies have mostly flamed out in clinical testing. “I hate saying this, but what helped me were the failed trials,” says Mahley, who this year raised US$63 million for his company E-Scape Bio to develop drugs that target the APOE4 protein. Those failures, he says, forced industry and funding agencies to rethink therapeutic strategies for tackling Alzheimer’s.
There’s the rub: it takes a certain confluence of biology, societal pressure, business opportunity and medical need for any gene to become more studied than any other. But once it has made it to the upper echelons, there’s a “level of conservatism”, says Gregory Radick, a science historian at the University of Leeds, UK, “with certain genes emerging as safe bets and then persisting until conditions change”.
The question now is how conditions might change. What new discoveries might send a new gene up the chart — and knock today’s top genes off their pedestal?
Nature 551, 427-431 (2017)
Sign up for the daily Nature Briefing email newsletter
Stay up to date with what matters in science and why, handpicked from Nature and other publications worldwide.